SEC Form 4 · accession 0001104659-15-015831
EPIRUS Biopharmaceuticals, Inc. · EPRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Wyand
Officer — See Remarks
Period of report
Feb 27, 2015
Accepted (ET)
Mar 2, 2015 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001135906
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $10.53 | Feb 27, 2015 | A | 79,461 | A | — | Feb 26, 2025 | Common Stock | 79,461 | 79,461 | D |
| Restricted Stock UnitsF2 | — | Feb 27, 2015 | A | 1,044 | A | — | — | Common Stock | 1,044 | 1,044 | D |
| Restricted Stock UnitsF3 | — | Feb 27, 2015 | A | 10,432 | A | — | — | Common Stock | 10,432 | 10,432 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest on the one year anniversary of the grant date and the remaining shares shall vest in substantially equal monthly installments over the next three (3) years, provided Reporting Person remains continuously employed by the Issuer through each vesting date.
- F2Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock, vests in full on the one year anniversary of the grant date provided Reporting Person remains continuously employed by the Issuer through the vesting date, and has no expiration date.
- F3Each RSU represents a contingent right to receive a share of the Issuer's common stock, vests in four (4) substantially equal annual installments beginning on the one year anniversary of the grant date provided Reporting Person remains continuously employed by the Issuer through each vesting date, and has no expiration date.
Remarks
SVP of Clinical, Regulatory & Manufacturing